Trial Profile
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Bone metastases; Germ cell and embryonal neoplasms; Germ cell cancer; Penile cancer; Primitive neuroectodermal tumours; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Testicular cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 03 Oct 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 01 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.